ArticlePharmaceutical research2004
Stable transfection of MDCK cells with epitope-tagged human PepT1.
Article in Pharmaceutical research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
- Differentiating passive from transporter-mediated uptake by PepT1: a comparison and evaluation of four methods.The Journal of surgical research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeEstablish and characterize a MDCK cell line that stably expressed PepT1.
methodsMDCK cells stably transfected with N-terminal HA-tagged hPepT1 were examined by immunostaining using antibodies to HA and hPepT1. HA-hPepT1 expression was verified by immunoprecipitation and Western blotting from cell lysates. The function of the expressed HA-hPepT1 was evaluated by glycyl-sarcosine uptake. The half-life of PepT1 on the cell surface was measured by biotinylation and chase-labeling of the cells, followed by immunoprecipitation with the anti-PepT1 antibody and blotting with HRP-streptavidin.
resultsImmunolabeling with antibodies to HA and PepT1 showed fluorescence colocalization. Immunoprecipitation with the anti-HA antibody and Western blotting with the anti-PepT1 antibody showed a broad 90-105 kDa band, and vice versa when the antibodies were utilized in the reverse order. Glycyl-sarcosine uptake was increased in the stably transfected cells by 2-5 fold over untransfected control cells. The Km value of 375 microM accurately reflected the characteristic low affinity of PepT1. Finally, the half-life of the surface biotinylated HA-hPepT1 was measured to be 22 hrs.
conclusionsA MDCK cell line stably expressed intact and functional HA-tagged hPepT1 on its cell surface. This cell line represents an alternative to the use of Caco-2 cells to evaluate PepT1 function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.